Leonid Capital Partners has now deployed more than $6.5 million in financing to Rx Bandz, supporting the continued development of the company’s next-generation drug delivery technologies.
This latest financing will support manufacturing and the final development activities required for the FDA submission of Rx Bandz’s MiniJect® auto-injector platform, while allowing the company to continue advancing innovative drug delivery technologies for both military and commercial applications.
Since its founding, Rx Bandz has secured more than $30 million in U.S. military R&D contracts to develop next-generation medical technologies designed to improve patient care and medical readiness. Today, the company is building on that momentum as it prepares for a significant regulatory milestone.
Congratulations to the entire Rx Bandz team on this milestone. We look forward to supporting your continued growth and the road ahead.
